Abstract
No public abstract is available from the verified source records.
Emily Tyksinski, Melanie S. Collins
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
European Respiratory Society and American Thoracic Society guidelines for the diagnosis of primary ciliary dyskinesia
10.1183/13993003.00745-2025 · 2025
Estimates of primary ciliary dyskinesia prevalence: a scoping review
10.1183/23120541.00989-2023 · 2024
Respiratory distress in the newborn with primary ciliary dyskinesia
2021
Diagnosing primary ciliary dyskinesia: an international patient perspective
10.1183/13993003.02018-2015 · 2016
Primary ciliary dyskinesia
10.1542/peds.2023-063064 · 2024
Recognizing clinical features of primary ciliary dyskinesia in the perinatal period
10.1038/s41372-024-02068-1 · 2024
Primary ciliary dyskinesia
10.1055/s-0035-1546748 · 2015
Primary ciliary dyskinesia
10.1016/j.chpulm.2023.100004 · 2023
The effect of intrapulmonary percussive ventilation in pediatric patients: a systematic review
10.1002/ppul.24135 · 2018
A comparison of intrapulmonary percussive ventilation and conventional chest physiotherapy for the treatment of atelectasis in the pediatric patient
10.1177/002013240204701006 · 2002
Efficacy of intrapulmonary percussive ventilation in a newborn with primary ciliary dyskinesia
10.1002/ppul.70995 · 2025
Beyond the present: current and future perspectives on the role of infections in pediatric PCD
10.3389/fped.2025.1564156 · 2025
Reducing exacerbations in children and adults with primary ciliary dyskinesia using erdosteine and/or azithromycin therapy (REPEAT trial): study protocol for a multicentre, double-blind, double-dummy, 2×2 partial factorial, randomised controlled trial
10.1136/bmjresp-2022-001236 · 2022
Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial
10.1016/s2213-2600(20)30058-8 · 2020
No additional external references are available.